Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response
Within the subgroup of patients with EGC and favorable pathologic responses (TRG 0-1) after NAT, the presence of postoperative ctDNA identified patients with elevated recurrence risk.
Authors
- Michael K. Gibson (ORCID: https://orcid.org/0000-0002-1500-9281)
- Eric Lander (ORCID: https://orcid.org/0000-0002-2843-7744)
- Cathy Eng (ORCID: https://orcid.org/0000-0003-2335-0612)
- Adham Jurdi (ORCID: https://orcid.org/0000-0002-2985-3053)
- Shruti Sharma
- Vasily N. Aushev (ORCID: https://orcid.org/0000-0001-8003-358X)
- Minetta C. Liu (ORCID: https://orcid.org/0000-0002-8206-5232)
- Brandon M. Huffman (ORCID: https://orcid.org/0000-0002-0768-3145)
- Jenifer Ferguson
- Samuel Jacob Klempner (ORCID: https://orcid.org/0000-0002-4062-0808)
- Punashi Dutta (ORCID: https://orcid.org/0000-0002-5963-7212)
- Diana L. Hanna (ORCID: https://orcid.org/0000-0003-2681-5032)
Institutions
- Vanderbilt University (US)
- Massachusetts General Hospital (US)
- USC Norris Comprehensive Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Natera (United States) (US)
- Minnesota Oncology (US)
- Vanderbilt-Ingram Cancer Center
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1200/po.24.00288
- Citations
- 4
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.29
Funders
- California Institute for Regenerative Medicine
- Conquer Cancer Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- American Society of Clinical Oncology
- Regeneron Pharmaceuticals
- National Comprehensive Cancer Network
- Mersana Therapeutics
- BeiGene
- Seagen
- Natera
- Springworks Therapeutics
- Coherus Biosciences
- Eisai
- Astellas Pharma
- Toray Industries
- Servier
- Geistlich Pharma
- Sumitomo Dainippon Pharma Oncology
- Genentech
- National Cancer Institute
- Daiichi Sankyo Europe